The antipoverty vaccines

Vaccine

Volumn 24, Issue 31-32, 2006, Pages 5787-5799

  Hotez, Peter J ^a   Ferris, Meghan T ^b,c  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c STONY BROOK UNIVERSITY   (United States)

Author keywords

Amebiasis; Antipoverty vaccines; Buruli ulcer; Chagas disease; Chlamydia infections; Hookworm; Leishmaniasis; Leprosy; Leptospirosis; Neglected tropical diseases; Schistosomiasis; Treponematoses

Indexed keywords

ALBENDAZOLE; AMEBIASIS VACCINE; ANTHELMINTIC AGENT; ANTIINFECTIVE AGENT; ANTIMONY DERIVATIVE; AZITHROMYCIN; BACTERIAL VACCINE; BCG VACCINE; BENZIMIDAZOLE; COCAINE CONJUGATED VACCINE; DENGUE VACCINE; DNA VACCINE; FLAVIVIRUS VACCINE; IVERMECTIN; LEISH 111F MPL; LEISHMANIA 111F 4' MONOPHOSPHORYL LIPID A VACCINE; LIVE VACCINE; MEBENDAZOLE; NA ANCYLOSTOMA SECRETED PROTEIN 2 HOOKWORM VACCINE; NICOTINE CHOLERA TOXIN B VACCINE; NICOTINE VACCINE; NIFURTIMOX; NORCOCAINE; ORAL POLIOMYELITIS VACCINE; PRAZIQUANTEL; RECOMBINANT ANTIGEN; RECOMBINANT VACCINE; SUCCINIC ANHYDRIDE; TA CD VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE; VIRUS VACCINE;

AMEBIASIS; BACTERIAL INFECTION; BIOINFORMATICS; BURULI ULCER; CHAGAS DISEASE; CHILD DEVELOPMENT; CHILD HEALTH; CHLAMYDIASIS; CLINICAL TRIAL; DEVELOPING COUNTRY; DRUG ABUSE; DRUG DEPENDENCE; ENDEMIC DISEASE; HEALTH PROGRAM; HOOKWORM; HOOKWORM INFECTION; HUMAN; LEISHMANIASIS; LEPROSY; LEPTOSPIROSIS; MATERNAL CARE; NONHUMAN; ONCHOCERCIASIS; PARASITOSIS; PATHOGENESIS; PERINATAL CARE; PLATYHELMINTH; PREGNANCY OUTCOME; PRIORITY JOURNAL; PRODUCTIVITY; REVIEW; RURAL AREA; SCHISTOSOMIASIS; SUBSTANCE ABUSE; TRACHOMA; TREPONEMA; TROPICAL DISEASE; URBAN AREA;

HUMANS; POVERTY; VACCINATION; VACCINES;

EID: 33745386210     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.05.008     Document Type: Review

References (131)

1. Sachs JD (chair). Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health 2001; World Health Organization.
2. Malaney P., Spielman A., and Sachs J.D. The malaria gap. Am J Trop Med Hyg 71 Suppl 2 (2004) 141-146
3. Russell S. The economic burden of illness for households in developing countries: a review of studies focusing on malaria, tuberculosis, and human immunodeficiency virus/acquired immunodeficiency syndrome. Am J Trop Med Hyg 71 Suppl 2 (2004) 147-155
4. Worrall E., Rietveld A., and Delacollette C. The burden of malaria epidemics and cost-effectiveness of interventions in epidemic situations in Africa. Am J Trop Med Hyg 71 Suppl 2 (2004) 136-140
5. Sachs J.D., and McArthur J.W. The Millennium Project: a plan for meeting the millennium development goals. Lancet 365 (2005) 347-353
6. Sachs J.D. The end of poverty (2005), The Penguin Press, New York pp. 210-25
7. World Health Organization. Annex Tables 2 and 3. The World Health Report 2004, changing history (2004), World Health Organization, Geneva p. 120-31
8. Hotez P.J., Molyneux D.H., Fenwick A., Ottesen E., Ehrlich Sachs S., and Sachs J.D. Incorporating a rapid-impact package for neglected tropical diseases with programs for HIV/AIDS, tuberculosis, and malaria. PLoS Med 3 (2006) e102
9. Hotez P.J., Ottesen E., Fenwick A., and Molyneux D. The neglected tropical diseases: the Ancient afflictions of stigma and poverty and the prospects for their control and elimination. Adv Exp Med Biol 582 (2006) 23-33
10. Klausner R.D., Fauci A.S., Corey L., Nabel G.S., Gayle H., Berkley S., et al. The need for a global HIV vaccine enterprise. Science 300 (2003) 2036-2039
11. Reed Z.H., Friede M., and Kieny M.P. Malaria vaccine development: progress and challenges. Curr Mol Med 6 (2006) 231-245
12. Young D., and Dye C. The development and impact of tuberculosis vaccines. Cell 124 (2006) 683-687
13. Molyneux D.H., Hotez P.J., and Fenwick A. "Rapid-impact interventions": how a policy of integrated control for Africa's neglected tropical diseases could benefit the poor. PLoS Med 2 (2005) e336
14. Hotez P.J. The "biblical diseases" and U.S. vaccine diplomacy. Brown World Aff J 12 (2006) 247-258
15. World Health Organization. Deworming for health and development. 2005; Report of the third global meeting of the partners for parasite control, Geneva, 29-30 November 2004. Geneva: World Health Organization. 51 p.
16. Bundy D.A. Population ecology of intestinal helminth infections in human communities. Philos Trans R Soc Lond B Biol Sci 321 (1988) 405-420
17. King C.H., Dickman K., and Tisch D.J. Reassessment of the cost of chronic helminthic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. Lancet 365 (2005) 1561-1569
18. Hotez P.J., Brooker S., Bethony J.M., Bottazzi M.E., Loukas A., et al. Hookworm infection. N Engl J Med 351 (2004) 799-807
19. World Bank. School deworming at a glance (2003), World Bank, Washington, DC. http://www.worldbank.org/hnp Available: http://www.worldbank.org/hnp
20. Sakti H., Nokes C., Hertanto W.S., Hendratno S., Hall A., Bundy D.A., et al. Evidence for an association between hookworm infection and cognitive function in Indonesia school children. Trop Med Int Health 4 (1999) 322-334
21. Nokes C., Grantham-McGregor S.M., Sawyer A.W., Cooper E.S., Robinson B.A., and Bundy D.A. Moderate to heavy infections of Trichuris trichiura affect cognitive function in Jamaican school children. Parasitology 104 (1992) 539-547
22. Jukes M.C., Nokes C.A., Alcock K.J., Lambo J.K., Kihamia C., Ngorosho N., et al. Heavy schistosomiasis associated with poor short-term memory and slower reaction times in Tanzanian schoolchildren. Trop Med Int Health 7 (2002) 104-117
23. Miguel E., and Kremer M. "Worms": identifying impacts on health and education in the presence of treatment externalities. Econometrica 72 (2004) 159-217
24. Bleakley H. Disease and development: evidence from the American South. J Eur Econ Assoc 1 (2003) 376-386
25. Savioli L., Engels D., and Endo H. Extending the benefits of deworming for development. Lancet 365 (2005) 1520-1521
26. Hotez PJ, Bethony J, Bottazzi ME, Brooker S, Diemert D, Loukas A. New technologies for the control of human hookworm infection. Trends Parasitol, 2006.
27. Capron A., Riveau G., Capron M., and Trottein F. Schistosomes: the road from host-parasite interactions to vaccines in clinical trials. Trends Parasitol 21 (2005) 143-149
28. Mung'Ala-Odera V., Snow R.W., and Newton C.R. The burden of neurocognitive impact associated with Plasmodium falciparum in Sub-Saharan Africa. Am J Trop Med Hyg 71 2 Suppl (2004) 64-70
29. Morrow C.E., Vogel A.L., Anthony J.C., Ofir A.Y., Dausa A.T., and Bandstra E.S. Expressive and receptive language functioning in preschool children with prenatal cocaine exposure. J Pediatr Psychol 29 (2004) 543-554
30. Singer L.T., Minnes S., Short E., Arendt R., Farkas K., Lewis B., et al. Cognitive outcomes of preschool children with prenatal cocaine exposure. J Am Med Assoc 291 (2004) 2448-2456
31. Meijler M.M., Matsushita M., Wirsching P., and Janda K.D. Development of immunopharmacotherapy against drugs of abuse. Curr Drug Discov Technol 1 (2004) 77-89
32. Guyatt H.L., and Snow R.W. Impact of malaria during pregnancy on low birth weight in Sub-Saharan Africa. Clin Microbiol Rev 17 (2004) 760-769
33. Menendez C. Malaria during pregnancy. Curr Mol Med 1 (2006) 269-273
34. Wickramasuriya G.A.W. The grave risks of hookworm disease as a complication of pregnancy. J Obstet Gynaecol Br Empire 42 (1935) 217-267
35. Bundy D.A., Chan M.S., and Savioli L. Hookworm infection in pregnancy. Trans R Soc Trop Med Hyg 89 (1995) 521-522
36. Shulman C.E., Graham W.J., Jilo H., Lowe B.S., New L., Obiero J., et al. Malaria is an important cause of anaemia in primigravidae: evidence from a district hospital in coastal Kenya. Trans R Soc Trop Med Hyg 90 (1996) 535-539
37. Guyatt H.L., Brooker S., Peshu N., and Shulman C.E. Hookworm and anaemia prevalence. Lancet 356 (2000) 2101
38. Christian P., Khatry S.K., and West K.P. Antenatal anthelmintic treatment, birth weight, and infant survival in rural Nepal. Lancet 364 (2004) 981-983
39. Ajanga A., Lwambo N.J., Blair L., Nyandindi U., Fenwick A., and Brooker S. Schistosoma mansoni in pregnancy and associations with anaemia in northwest Tanzania. Trans R Soc Trop Med Hyg 100 (2006) 59-63
40. Gallagher M., Malhotra I., Mungai P.L., Wamachi A.N., Kioko J.M., Ouma J.H., et al. The effects of maternal helminth and malaria infections on mother-to-child HIV transmission. AIDS 19 (2005) 1849-1855
41. Gilson G.J., Harner K.A., Abrams J., Izquierdo L.A., and Curet L.B. Chagas disease in pregnancy. Obstet Gynaecol 86 (1995) 646-647
42. Moretti E., Basso B., Castro I., Paez M.C., Chaul M., Barbieri G., et al. Chagas' disease: study of congenital transmission in cases of acute maternal infection. Rev Soc Brasil Med Trop 38 (2005) 53-55
43. Sanchez-Negrette O., Mora M.C., and Basombrio M.A. High prevalence of congenital Trypanosoma cruzi infection and family clustering in Salta, Argentina. Pediatrics 115 (2005) e668-e672
44. Hermann E., Truyens C., Alonso-Vega C., Rodriguez P., Berthe A., Torrico F., et al. Congenital transmission of Trypanosoma cruzi is associated with maternal enhanced parasitemia and decreased production of interferon-gamma in response to parasite antigens. J Infect Dis 189 (2004) 1274-1281
45. Schmid G. Economic and programmatic aspects of congenital syphilis prevention. Bull WHO 82 (2004) 402-409
46. Woods C.R. Syphilis in children: congenital and acquired. Semin Pediatr Infect Dis 16 (2005) 245-257
47. Gust D.A., Levine W.C., St. Louis M.E., Braxton J., and Berman S.M. Mortality associated with congenital syphilis in the United States, 1992-1998. Pediatrics 109 (2002) E79
48. Figueiro-Filho E.A., Duarte G., El-Beitune P., Quintana S.M., and Maia T.L. Visceral leishmaniasis (kala-azar) and pregnancy. Infect Dis Obstet Gynecol 12 (2004) 31-40
49. Pagliano P., Carannante N., Rossi M., Gramiccia M., Gracloni L., Faella F.S., et al. Visceral leishmaniasis in pregnancy: a case series and systematic review of the literature. J Antimicrob Chemother 55 (2005) 229-233
50. Thangappah R.B.P. Maternal and perinatal outcome with drug abuse in pregnancy. J Obstet Gynaecol 20 (2000) 597-600
51. Ludlow J.P., Evans S.F., and Hulse G. Obstetric and perinatal outcomes in pregnancies associated with illicit substance abuse. Aust N Z J Obstet Gynaecol 44 (2004) 302-306
52. Sprauve M.E., Lindsay M.K., Herbert S., and Graves W. Adverse perinatal outcome in parturients who use crack cocaine. Obstet Gynaecol 89 (1997) 674-678
53. Rizk B., Atterbury J.L., and Groome L.J. Reproductive risks of cocaine. Human Reprod Update 2 (1996) 43-55
54. Hopkins D.R., Ruiz-Tiben E., Downs P., Withers Jr. P.C., and Maguire J.H. Dracunculiasis eradication: the final inch. Am J Trop Med Hyg 73 (2005) 669-675
55. Ramaiah K.D., Guyatt H., Ramu K., Vanamail P., Pani S.P., and Das P.K. Treatment costs and loss of work time to individuals with chronic lymphatic filariasis in rural communities in South India. Trop Med Int Health 4 (1999) 19-25
56. Ramaiah K.D., Radhamani M.P., John K.R., Evans D.B., Guyatt H., Joseph A., et al. The impact of lymphatic filariasis on labour inputs in southern India: results of a multi-site study. Ann Trop Med Parasitol 94 (2000) 353-364
57. Ramaiah K.D., Kumar K.N., Ramu K., Pani S.P., and Sas P.K. Functional impairment caused by lymphatic filariasis in rural areas of south India. Trop Med Int Health 2 (1997) 832-838
58. Dias J.C., Silveira A.C., and Schofield C.J. The impact of Chagas disease control in Latin America: a review. Mem Inst Oswaldo Cruz 97 (2002) 603-612
59. Moncayo A. Chagas disease: current epidemiological trends after the interruption of vectorial and transfusional transmission in the Southern Cone countries. Mem Inst Oswaldo Cruz 98 (2003) 577-591
60. Ahluwalia I.B., Bern C., Costa C., Akter T., Chowdhury R., Ali M., et al. Visceral leishmaniasis: consequences of a neglected disease in a Bangladeshi community. Am J Trop Med Hyg 69 (2003) 624-628
61. Adhikari S.R., and Maskay N.M. The economic burden of Kala-azar in households of the Danusha and Mahottari districts of Nepal. Acta Trop 88 (2003) 1-2
62. Benton B. Economic impact of onchocerciasis control through the African Programme for Onchocerciasis Control: an overview. Ann Trop Med Parasitol 92 Suppl 1 (1998) S33-S39
63. Waters H.R., Rehwinkel J.A., and Burnham G. Economic evaluation of mectizan distribution. Trop Med Int Health 9 Suppl (2004) 16a-25a
64. Frick K.D., Colchero M.A., and Dean D. Modeling the economic net benefit of a potential vaccination program against ocular infection with Chlamydia trachomitis. Vaccine 22 (2005) 689-696
65. Crosby W.H. The hematology of hookworm disease. Contribution of Bailey K. Ashford. P R Health Sci J 4 (1985) 113-119
66. Crosby W.H. The deadly hookworm. Why did the Puerto Ricans die?. Arch Intern Med 147 (1987) 577-578
67. Darling ST, Smilie WG. Studies on Hookworm Infection in Brazil, No. 14. Monogr. Rockefeller Institute of Medical Research; 1921. 42 pp.
68. Faust E.C. Human helminthology (1929), Lea & Febiger, Philadelphia p. 375
69. Chandler AC. Hookworm disease. Its distribution, biology, epidemiology, pathology, diagnosis, treatment and control. New York: Macmillan; 1929.
70. Weisbrod B.A., and Helminiak T.W. Parasitic diseases and agricultural labor productivity. Econ Dev Cultural Change 25 (1977) 505-522
71. Gilgen D., Mascie-Taylor C.G.N., and Roetta L. Intestinal helminth infections, anaemia, and labour productivity of female tea pluckers in Bangladesh. Trop Med Int Health 6 (2001) 449-451
72. Guyatt H. Do intestinal nematodes affect productivity in adulthood?. Parasitol Today 16 (2000) 153-158
73. Fenwick A., and Figenschou B.H. The effect of Schistosoma mansoni infection of the productivity of cane cutters on a sugar estate in Tanzania. Bull World Health Organ 47 (1972) 567-572
74. Kamel M.I., Moustafa Y.A., Foda N., Khashab S., Moemen M., and Abo el-Naga R.M. Impact of schistosomiasis on quality of life and productivity of workers. East Mediterr Health J 8 (2002) 354-362
75. Babu B.V., Nayak A.N., Dhal K., Acharya A.S., Jangid P.K., and Mallick G. The economic loss due to treatment costs and work loss to individuals with chronic lymphatic filariasis in rural communities of Orissa, India. Acta Trop 82 (2002) 31-38
76. McKenzie F.E. Polyparasitism. Int J Parasitol 34 (2005) 221-222
77. Raso G., Luginbhuhl A., Adjoua C.A., Tian-Bi N.T., Silue K.D., Matthys B., et al. Multiple parasite infections and their relationship to self-reported morbidity in a community of rural Cote d'Ivoire. Int J Epidemiol 33 (2004) 1092-1102
78. Ehrenberg J.P., and Ault S.K. Neglected diseases of neglected populations: thinking to reshape the determinants of health in Latin America and the Caribbean. BMC Public Health 5 (2005) 119
79. Fenwick A., Molyneux D., and Nantulya V. Achieving the millennium development goals. Lancet 365 (2005) 1029-1030
80. Brooker S, Clements ACA, Hotez PJ, Hay SI, Tatem A, Bundy DAP, et al. The burden and distribution of hookworm and malaria co-infection among African schoolchildren, submitted for publication.
81. Fincham J.E., Markus M.B., and Adams V.J. Could control of soil-transmitted helminthic infection influence the HIV/ADIS pandemic. Acta Trop 86 (2003) 315-333
82. Druilhe P., Tall A., and Sokhna C. Worms can worsen malaria: towards a new means to roll back malaria?. Trends Parasitol 21 (2005) 359-362
83. Sachs J.D., and Hotez P.J. Fighting tropical diseases. Science 311 (2006) 1521
84. Hotez P.J. Reverse vaccinology for human parasitic infections and the role of innovative developing countries. Parasite Immunol 28 (2006) 242
85. Bottazzi M.E., Miles A.P., Diemert D.J., and Hotez P.J. An ounce of prevention on a budget: a non-profit approach to developing against neglected diseases. Expert Rev Vaccines 5 (2006) 189-198
86. Loukas A, Bethony J, Brooker S, Hotez P. Hookworm vaccines-past, present and future. Lancet Infect Dis, in press.
87. Goud G.N., Bottazzi M.E., Zhan B., Mendez S., Deumic V., Pleiskatt J., et al. Expression of the Necator americanus hookworm larval antigen Na-ASP-2 in Pichia pastoris and purification of the recombinant protein for use in human clinical trials. Vaccine 23 (2005) 4754-4764
88. Awadzi K., Boakye D.A., Edwards G., Opoku N.O., Attah S.K., Osei-Atweneboana M.Y., et al. An investigation of persistent microfilaridermias despite multiple treatments with ivermectin in two onchocerciasis-endemic foci in Ghana. Ann Trop Med Parasitol 98 (2004) 231-249
89. Lustigman S., James E.r., Tawe W., and Abraham D. Towards a recombinant antigen vaccine against Onchocerca volvulus. Trends Parasitol 18 (2002) 135-141
90. Nutman T.B. Future directions for vaccine-related onchocerciasis research. Trends Parasitol 18 (2002) 237-239
91. MacDonald A.J., Tawe W., Leon O., Cao L., Liu J., Oksov Y., et al. Ov-ASP-1, the Onchocerca volvulus homologue of the activation associated secreted protein family is immunostimulatory and can induce protective anti-larval immunity. Parasite Immunol 26 (2004) 53-62
92. Bergquist N.R., Leonardo L.R., and Mitchell G.F. Vaccine-linked chemotherapy: can schistosomiasis control benefit from an integrated approach?. Trends Parasitol 21 (2005) 112-117
93. Dalton J.P., Neill S.O., Stack C., Collins P., Walsh A., Sekiya M., et al. Fasciola hepatica cathepsin L-like proteases: biology, function, and potential in the development of first generation liver fluke vaccines. Int J Parasitol 33 (2003) 1173-1181
94. Lightowlers M.W. Vaccines against cysticercosis and hydatidosis: foundations in taeniid cestode immunology. Parasite Int 55 Suppl (2006) S34-S43
95. Schmunis GA. American trypanosomiasis and its impact on public health in the Americas [in Portuguese]. In: Breneer Z., Andrade Z.A., and Barral-Netto M. (Eds). Trypanosoma cruzi e Doenca de Chagas (2000), Guanabara Koogan, Rio de Janeiro 1-20
96. Loftus B., Anderson I., Davies R., Alsmark U.C., Samuelson J., Amedeo P., et al. The genome of the proteist parasite Entamoeba histolytica. Nature 433 (2005) 865-868
97. El-Sayed N.M., Myler P.J., Bartholomeu D., Nilsson D., Aggarwal G., Tran A.N., et al. The genome sequence of Trypanosoma cruzi, etiologic agent of Chagas disease. Science 309 (2005) 409-415
98. El-Sayed N.M., Myler P.J., Blandin G., Berrlman M., Crabtree J., Aggarwal G., et al. Comparative genomics of trypanosomatid parasitic protozoa. Science 309 (2005) 404-409
99. Stober C.B., Lange U.G., Roberts M.T., Gilmartin B., Francis R., Almelda R., et al. From genome to vaccines for leishmaniasis: screening 100 novel vaccine candidates against murine Leishmania major infection. Vaccine 24 (2006) 2602-2616
100. Cifuentes E., Blumental U., Ruiz-Palacios G., Bennett S., and Peasey A. Epidemiologic setting of the agricultural use of sewage: Valle del Mezquital, Mexico [Spanish]. Salud Publica Mexico 36 (1994) 3-9
101. Snow M.J., and Stanley Jr. S.L. Recent progress in vaccines for amebiasis. Arch Med Res 37 (2006) 280-287
102. Bujanover S., Katz U., Bracha R., and Mirelman D. A virulence attenuated amoebapore-less mutant of Enatmoeba histolytica and its interaction with host cells. Int J Parasitol 33 (2003) 1655-1663
103. Haque R., Ali I.M., Sack R.B., Farr B.M., Ramakrishnan G., and Petri Jr. W.A. Amebiasis and mucosal IgA antibody against the Entamoeba histolytica adherence lectin Bangladeshi children. J Infect Dis 182 (2001) 1787-1793
104. Petri Jr. W.A., and Ravdin J.I. Protection of gerbils from amebic liver abscess by immunization with the galactose-specific adherence lectin of Entamoeba histolytica. Infect Immun 59 (1990) 97-101
105. Villar J.C., Marin-Neto J.A., Ebrahim S., and Yusuf S. Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection. Cochrane Database Syst Rev (2002) CD003463
106. Wizel B., Palmieri M., Mendoza C., Arana B., Sidney J., Sette A., et al. Human infection with Trypanosoma cruzi induces parasite antigen-specific cytotoxic T lymphocyte responses. J Clin Invest 102 (1998) 1062-1071
107. Chamond N., Coatnoan N., and Minoprio P. Immunotherapy of Trypanosoma cruzi infections. Curr Drug Targets Immune Endocr Metabol Disord 2 (2002) 247-254
108. Wizel B., Nunes M., and Tarleton R.L. Identification of Trypanosoma cruzi trans-sialidase family members as targets of protective CD8+ TC1 responses. J Immunol 159 (1997) 6120-6130
109. Wizel B., Garg N., and Tarleton R.L. Vaccination with trypomastigote surface antigen 1-encoding plasmid DNA confers protection against lethal Trypanosoma cruzi infection. Infect Immun 66 (1998) 5073-5081
110. Fralish B.H., and Tarleton R.L. Genetic immunization with LYT1 or a pool of trans-sialidase genes protects mice from lethal Trypanosoma cruzi infection. Vaccine 21 (2003) 3070-3080
111. Tarleton R.L. New approaches in vaccine development for parasitic infections. Cell Microbiol 7 (2005) 1379-1386
112. Tarleton R.L. The Trypanosoma cruzi proteome. Science 309 (2005) 473-476
113. Coler R.N., and Reed S.G. Second-generation vaccines against leishmaniasis. Trends Parasitol 21 (2005) 244-249
114. Vandahl B.B., Birkelund S., and Christiansen G. Genome and proteome analysis of Chlamydia. Proteomics 4 (2004) 2831-2842
115. McKevitt M., Brinkman M.B., McLoughlin M., Perez C., Howell J.K., Weinstock G.M., et al. Genome scale identification of Treponema pallidum antigens. Infect Immun 73 (2005) 4445-4450
116. Gamberini M., Gomez R.M., Atzingen M.V., Martins E.A., Vasconcellos S.A., Romero E.C., et al. Whole-genome analysis of Leptospira interrogans to identify vaccine candidates against leptospirosis. FEMS Microbiol Lett 244 (2005) 305-313
117. Reed SG. Leprosy vaccine update, May 2005; http://www.leprosy.org/PDF/M2005LeprosyProjectUpdate4.pdf.
118. Huygen K. Prospects for vaccine development against Buruli disease. Expert Rev Vaccines 2 (2003) 561-569
119. Mariotti S. New steps toward eliminating blinding trachoma. N Engl J Med 351 (2004) 2004-2007
120. Igietseme J., Eko F., He Q., Handea C., Lubitz W., Garcia-Sastre A., et al. Delivery of Chlamydia vaccines. Expert Opin Drug Deliv 2 (2005) 549-562
121. In: Woodall JP (Ed). Proceedings of the Chlamydia Vaccine Development Colloquium (2004), The Albert B. Sabin Vaccine Institute
122. Rupp R.E., Stanberry L.R., and Rosenthal S.L. Vaccines for sexually transmitted infections. Pediatr Ann 34 (2005) 818-820
123. Setia M.S., Steinmaus C., Ho C.S., and Rutherford G.W. The role of BCG in prevention of leprosy: a meta-analysis. Lancet Infect Dis 6 (2006) 162-170
124. Koizumi N., and Watanabe H. Leptospirosis vaccines: past, present, and future. J Postgrad Med 51 (2005) 210-214
125. Cullen P.A., and Cameron C.E. Progress towards an effective syphilis vaccine: the past, present and future. Expert Rev Vaccines 5 (2006) 67-80
126. Pugachev K.V., Guirakhoo F., and Monath T.P. New developments in flavivirus vaccines with special attention to yellow fever. Curr Opin Infect Dis 18 (2005) 387-394
127. Shepard D.S., Suaya J.A., Halstead S.B., Nathan M.B., Gubler D.J., Mahoney R.T., et al. Cost-effectiveness of a pediatric dengue vaccine. Vaccine 22 (2004) 1275-1280
128. Lang J., and Wood S.C. Development of orphan vaccines: an industry perspective. Emerg Infect Dis 5 (1999) 749-754
129. Levine R, Kremer M, Albright A (co-chairs). Making markets for vaccines, ideas to action. The report of the Center for Global Development Advance Market Commitment Group 2005; Center for Global Development, 113 p.
130. Morel C., Acharya T., Broun D., Dangi A., Elias C., Ganguly N.K., et al. Health innovation networks to help developing countries address neglected diseases. Science 309 (2005) 401-404
131. Canning D. Priority setting and the 'neglected' tropical diseases. Trans R Soc Trop Med Hyg 100 (2006) 499-504